AK
AKBLF.US ALK-Abelló A/S
- Market cap
- USD 8.10B
- P/E
- 38.4x
- P/B
- 7.81x
- ROE
- 22.4%
- Dividend yield
- 0.67%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is AKBLF.US undervalued?
Graham numberThe Graham number of ALK-Abelló A/S cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ALK-Abelló A/S fundamental analysis
No fundamental analysis for ALK-Abelló A/S yet.
ALK-Abelló A/S stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ALK-Abelló A/S
ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally. The company offers allergy immunotherapy products in the form of vaccines, injections, sublingual drops, and tablets for the treatment of various allergies, including grass and tree pollen, house dust mites, ra…
Full company profileALK-Abelló A/S financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ALK-Abelló A/S annual financial statements (DKK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.01B | 2.91B | 2.92B | 3.27B | 3.49B | 3.92B | 4.51B | 4.82B | 5.54B | 6.30B | 7.12B |
| Gross Profit | 2.01B | 1.64B | 1.63B | 1.89B | 2.03B | 2.40B | 2.79B | 3.04B | 3.55B | 4.15B | 4.84B |
| Operating Income | 479M | -80.0M | -96.0M | -14.0M | 150M | 292M | 470M | 666M | 1.09B | 1.66B | 2.03B |
| EBITDA | 664M | 84.4M | 112M | 232M | 419M | 544M | 709M | 913M | 1.39B | 1.99B | 2.37B |
| Net Income | 270M | -158M | -170M | -50.0M | 25.0M | 219M | 335M | 486M | 815M | 1.19B | 1.55B |
| EPS | 1.36 | -0.79 | -0.78 | -0.23 | 0.11 | 0.99 | 1.51 | 2.20 | 3.68 | 5.38 | 6.99 |
| Balance Sheet | |||||||||||
| Total Assets | 4.80B | 4.96B | 4.87B | 5.50B | 5.56B | 5.83B | 6.31B | 6.73B | 8.25B | 9.15B | 9.69B |
| Total Liabilities | 1.92B | 1.67B | 1.69B | 2.32B | 2.41B | 2.35B | 2.32B | 2.28B | 2.87B | 2.72B | 2.77B |
| Shareholders' Equity | 2.88B | 3.29B | 3.18B | 3.18B | 3.15B | 3.48B | 3.99B | 4.45B | 5.37B | 6.43B | 6.92B |
| Cash & Short-term Investments | 840M | 711M | 396M | 316M | 298M | 194M | 221M | 474M | 589M | 1.24B | 1.73B |
| Total Debt | 775M | 758M | 742M | 990M | 943M | 710M | 696M | 765M | 1.19B | 418M | 420M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 405M | -387M | -95.0M | 132M | 301M | 468M | 416M | 667M | 1.21B | 1.81B | 2.10B |
| Capital Expenditure | 225M | 267M | 178M | 167M | 222M | 263M | 298M | 379M | 1.30B | 275M | 186M |
| Free Cash Flow | 180M | -654M | -273M | -35.0M | 79.0M | 205M | 63.0M | 288M | -90.0M | 1.54B | 1.91B |
| Ratios | |||||||||||
| ROE | 9.4% | -4.8% | -5.3% | -1.6% | 0.8% | 6.3% | 8.4% | 10.9% | 15.2% | 18.6% | 22.4% |
| ROA | 5.6% | -3.2% | -3.5% | -0.9% | 0.4% | 3.8% | 5.3% | 7.2% | 9.9% | 13.1% | 16.0% |
| Net Profit Margin | 9.0% | -5.4% | -5.8% | -1.5% | 0.7% | 5.6% | 7.4% | 10.1% | 14.7% | 19.0% | 21.8% |
| Debt to Equity | 0.27x | 0.23x | 0.23x | 0.31x | 0.30x | 0.20x | 0.17x | 0.17x | 0.22x | 0.07x | 0.06x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ALK-Abelló A/S dividends
- Dividend yield
- 0.67%
- Forward dividend
- 0.25 USD
- Payout ratio
- -
- Ex-dividend date
- Mar 17, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | DKK 24.0M | 0.11 | 96.0% |
| 2019 | DKK 24.0M | 0.11 | - |
| 2018 | - | - | - |
| 2017 | DKK 51.0M | 0.26 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:1 on Mar 28, 2022.
Who owns ALK-Abelló A/S
- Insiders 0.00%
- Institutions 63.80%
- Public & others 36.20%
- Shares outstanding 202M
- Free float 132M
ALK-Abelló A/S company profile
- Company name
- ALK-Abelló A/S
- Ticker
- AKBLF.US
- ISIN
- DK0060027142
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,773
- Fiscal year end
- December
- Address
- Bøge Allé 6-8, Horsholm, Denmark, 2970
- Phone
- 45 45 74 75 76
- Website
- alk.net
About ALK-Abelló A/S
ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally. The company offers allergy immunotherapy products in the form of vaccines, injections, sublingual drops, and tablets for the treatment of various allergies, including grass and tree pollen, house dust mites, ragweed, Japanese cedar, peanuts, and tree nuts; adrenaline nasal sprays for emergency treatment of anaphylaxis and acute flares in chronic spontaneous urticaria; and ALK 014, a biologic for food allergies. It also provides GRAZAX/GRASTEK, a tablet for grass pollen allergy; ACARIZAX, ODACTRA, and MITICURE/SENSIMUNE, which are tablets for house dust mite allergies; ITULAZAX/ITULATEK, a tablet for tree pollen allergy; RAGWITEK/RAGWIZAX, a tablet for ragweed pollen allergy; and CEDARCURE, a tablet for Japanese cedar pollen allergy. In addition, the company offers consumer healthcare solutions, such as klarify.me, a digital patient engagement platform to help people manage their allergies. Further, it provides allergen extracts for use in the diagnosis of specific allergies, such as skin prick and blood test; and emergency medicine treatment, such as adrenaline autoinjectors, an intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including anaphylaxis. The company has a collaboration with Torii Pharmaceutical Co., Ltd. for the development of GRAZAX and CEDARCURE; and Dr. Reddy's Laboratories for the development of Sensimune. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark.
ALK-Abelló A/S management
10- Mr. Peter HallingPresident, CEO & Member of Management Board · born 1977
- Mr. Claus Steensen SoljeExecutive VP of Global Business Operations, CFO & Member of Management Board · born 1972
- Mr. Søren Daniel NiegelMember of Management Board · born 1971
- Ms. Katja Barnkob ThalundSenior Project Director, Global Clinical Development & Employee-elected Director · born 1969
- Ms. Nanna Rassov CarlsonSenior Manager of QA Release & Employee Representative Director · born 1976
- Mr. Johan SmedsrudSenior Maintenance Supporter of Process & Production Support & Employee Representative Director · born 1972
- Ms. Lise Lund MaerkedahlProject Director of Global Clinical Development & Employee-elected Director · born 1967
- Mr. Per PlotnikofVP of Corporate Communications, Investor Relations & Strategic Planning and Head of IR
- Ms. Lika ThiesenExecutive Vice President of Global People & Organisation · born 1975
- Prof. Hendrik Kees Kam Nolte M.D., Ph.D.Senior Vice President of Research & Development - North America and International Markets